Literature DB >> 7736916

Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).

S el Mansouri1, M Tod, M Leclerq, O Petitjean, G Perret, M Porthault.   

Abstract

The kinetics of all-trans-retinoic (RA) acid are known to be nonlinear. To clarify the mechanisms involved, RA kinetics were determined in four groups of rats: group 1 received a single 2-mg RA dose intravenously (N = 5); group 2 received the same treatment as group 1 after 12 days of oral RA (2 mg/day) (N = 6); group 3 received a single, oral 2-mg (N = 6) or 5-mg RA dose (N = 6); and group 4 (N = 5 + 3) received the same treatment as group 3 after 12 days of oral RA (2 mg/day). Blood samples, 10-12/animal, were taken during the 7 hr following the final dosage. Plasma RA concentrations were determined by liquid chromatography. Noncompartmental analysis showed that RA disposition after intravenous bolus dosing obeyed Michaelis-Menten (MM) kinetics in group 1 (no pretreatment) and linear kinetics in group 2 (pretreated), with a lower area under the concentration vs. time curve, which suggested time-dependent kinetics with autoinduction. The same autoinduction phenomenon was observed after oral dosing in groups 3 and 4. Moreover, the mean area under the concentration vs. time curve was not higher after 5 mg dosing than after 2 mg dosing, which indicated a saturable mechanism of absorption. Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02). The volume of distribution also decreased after pretreatment, which indicated a modification in tissular distribution (565 vs. 358 ml, p < 0.001, group 3 vs. 4).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7736916

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Multiple cytochrome P-450 genes are concomitantly regulated by vitamin A under steady-state conditions and by retinoic acid during hepatic first-pass metabolism.

Authors:  A Catharine Ross; Christopher J Cifelli; Reza Zolfaghari; Nan-Qian Li
Journal:  Physiol Genomics       Date:  2010-11-02       Impact factor: 3.107

2.  Lipopolysaccharide opposes the induction of CYP26A1 and CYP26B1 gene expression by retinoic acid in the rat liver in vivo.

Authors:  Reza Zolfaghari; Christopher J Cifelli; Siam O Lieu; Qiuyan Chen; Nan-qian Li; A Catharine Ross
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-12-21       Impact factor: 4.052

Review 3.  Clinical pharmacokinetics of tretinoin.

Authors:  M B Regazzi; I Iacona; C Gervasutti; M Lazzarino; S Toma
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

4.  Retinoids synergize with insulin to induce hepatic Gck expression.

Authors:  Guoxun Chen; Yan Zhang; Danhong Lu; Nan-Qian Li; A Catharine Ross
Journal:  Biochem J       Date:  2009-05-01       Impact factor: 3.857

5.  Cloning and molecular expression analysis of large and small lecithin:retinol acyltransferase mRNAs in the liver and other tissues of adult rats.

Authors:  Reza Zolfaghari; Yuanping Wang; Qiuyan Chen; Anne Sancher; A Catharine Ross
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

6.  Pharmacokinetics of the time-dependent elimination of all-trans-retinoic acid in rats.

Authors:  Anas Saadeddin; Francisca Torres-Molina; Jaime Cárcel-Trullols; Amparo Araico; José-Esteban Peris
Journal:  AAPS PharmSci       Date:  2004-01-09

Review 7.  Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.

Authors:  Cara H Nelson; Brian R Buttrick; Nina Isoherranen
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

8.  Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off.

Authors:  M B Regazzi; D Russo; I Iacona; S Sacchi; G Visani; M Lazzarino; G Avvisati; P G Pelicci; G Dastoli; C Grandi; S Spreafico; R Grattoni; P Galieni; S Rupoli; A M Maiolo; E Guerra; A M Liberati
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 9.  Regulatory T cells in many flavors control asthma.

Authors:  A Ray; A Khare; N Krishnamoorthy; Z Qi; P Ray
Journal:  Mucosal Immunol       Date:  2010-02-17       Impact factor: 7.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.